UCD Home | About UCD | UCD News & Events | Virtual Tour | Contact UCD | Staff Directories | UCD Sitemap | UCD Connect
Inquire, Innovate, Translate...
UCD Conway Institute is an interdisciplinary research centre exploring fundamental mechanisms of chronic disease for novel diagnostic & therapeutic solutions

The following should only be Cancer ONLY people

Keywords: Ovarian cancer, diagnostics, neurodegeneration, Alzheimer's disease, MCI, adaptive immunity

We study proteins and the immune response in patients with auto-immune diseases and cancer. Our aim is to identify patterns of proteins that can be used to better diagnose diseases, which can lead to better treatments and a higher cure rate for patients.


Keywords: cancer, breast cancer, biomarkers, therapy

Development of new biomarkers and therapeutics for breast cancer

Keywords: Lipid metabolism, insulin signalling, gene expression, cell cycle regulation.

The group works on the SREBP family of transcription factors that control cholesterol and lipid metabolism and play critical roles during adipocyte differentiation and insulin-dependent gene expression. Disturbances in lipid metabolism are at the very core of several major health issues facing modern society, including cardiovascular disease, obesity and diabetes. So, the factors and signals that regulate the function of the SREBP family of proteins are very relevant to metabolic disease.


Keywords: functional genomics, molecular diagnostics, in vivo imaging, breast cancer, melanoma, biomarkers, tissue microarrays

The identification and validation of biomarkers of breast cancer and melanoma is a major research focus in our group. Biomarkers act as a signature for a specific disease and are used to develop diagnostic tests, enable more targeted treatment strategies and can provide rapid information on the effectiveness of cancer treatment.

Keywords: drug development, protide drugs, nucleoside drugs, novel sugars

Nucleosides are an important drug class that includes some well-known anti-viral and anti-cancer drugs such as Zovirax (cold sores), AZT (HIV) and Gemzar (anti-cancer). There is a limitation on the development of such drugs as their activation within the target cells in the body often is not very efficient. We discovered an easy way to make phosphorus compounds for use in the structure of ‘ProTide’ drugs to enable the self-activation of these nucleosides.

Keywords: neurodegeneration, neurotherapeutics, neurogenetics, visual function, anti-angiogenetic drugs, developmental and pathological angiogenesis

We focus on genetic pathways and the pharmacological agents that modulate visual function and disease. We use genetic approaches to identify genes and pathways that mediate eye development, development of visual function and cone photoreceptor function. In parallel, we apply random and targeted small molecule drug screens to identify novel compounds that inhibit intraocular angiogenesis in the eye or drugs that modulate vision function in vivo.

Keywords: systems medicine, network fragilities, therapeutical targets, drug combinations

My group employs systems biology driven discovery and validation approaches to develop quantitative, dynamic models of signalling and gene networks that control cellular responses to external cues and thereby cell fate decisions

Keywords: signal transduction, systems biology, proteomics, cancer biology

My research is focused across three areas: MAPK signalling, proteomics, and cancer research, especially in regard to using systems biology approaches.

Keywords: cell death, cell division, mitosis, anti-mitotic agents

Our research is focused on further understanding the molecular mechanisms of cell division and cell death and how crosstalk between these distinct processes regulates cell fate. We are examining the precise role of mitotic kinases and phosphatases as key upstream regulators of cell death.

Keywords: chemoresistance, epigenetic reprogramming in hypoxia, miRNA targeting and regulation, senescence, autophagy

My research interests focus on the mechanisms underlying Paclitaxel chemoresistance for patients presenting with epithelial ovarian cancer and breast cancer, specifically triple negative breast cancer. I also focus on how DNA methylation and histone modifications are altered in hypoxia and how this relates to ultimate chemoresistance and retention of cellular viability in the face of chemotherapeutic engagement.

Keywords: Diabetes, renal pathophysiology, chemoresistance, cancer biology, fibrogenesis, stenosis, biomarkers

The focus of my research is the identification and functional characterisation of novel therapeutic targets with the aim of developing improved therapeutics and diagnostics for fibrotic disease (including diabetic kidney disease) and more recently for cancer.

Keywords: Haemostasis, thrombosis, vascular biology, maternal health, cancer metastasis

My principal research focus is to investigate the role of coagulation and inflammation in human disease, particularly in disorders affecting maternal health. Current funded projects include investigating coagulation activation in early onset preeclampsia, a disorder associated with maternal and fetal morbidity and mortality; and optimising low molecular weight heparin (LMWH) endothelial protective properties in an effort to identify novel prevention strategies in cancer metastasis.


Keywords: high content imaging, predictive toxicology, cardiac biomarkers

We have invented and validated a predictive cell-based assay for screening drug candidates for their risk of producing idiosyncratic hepatotoxicity and various other toxicities. We are further developing this method to enhance its user-friendliness and predictive effectiveness as well as adapting it for use in detection of on-going toxicity in vivo.

Keywords: medical devices, microfluidic devices, cell biomechanics

I am interested in working with clinicians and scientists to identify clinical needs and develop appropriate solutions with a strategic focus on targeted, minimally invasive delivery of next-generation therapeutics

Keywords: Proteomics, prostate cancer, psoriatic arthritis, biomarker discovery, biomarker evaluation, radiation therapy, patient engagement

Current interests and funded projects focus on the discovery, measurement and evaluation of protein biomarkers. We aim to progress protein biomarkers from discovery to clinical utility in the areas of oncology and inflammatory disease. We also investigate mechanisms of disease progression focusing on prostate cancer and psoriatic arthritis. We have recently used LC-MS/MS methods to characterise protein expression in discrete regions of prostate tumour following isolation of tumour tissue material by laser capture micro dissection.

Keywords: Cancer, epigenetics, prostate cancer, DNA methylation, biomarkers, urine, liquid biopsies

My research interests are focused on translational prostate cancer epigenetics; understanding the role of epigenomic aberrations in the pathogenesis of prostate cancer and harnessing these aberrations to develop prognostic and predictive biomarkers. My group has a particular interest in studying DNA methylation changes in the prostate gland and in 'liquid biopsies' that can act as surrogates for non-invasive tumour detection and monitoring.


Keywords: biomarkers, prostate cancer, targeted agents, hormone therapies, validation, proteomics

My focus of research is in prostate cancer with specific interests in 1) Biomarker discovery and validation for grade and stage of prostate cancer to inform appropriate treatment strategies; 2) Understanding the mechanisms of resistances to therapy of advanced disease.


Keywords: carbohydrate chemistry

We develop new methodologies for the synthesis of carbohydrate and glycoconjugates, including development of new glycosylation methods. Also, we are interested in the synthesis of thioglycoside analogues of natural carbohydrates and glycoconjugates .

YouTube LinkedIn Twitter Image Map